Terms: = Bone cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568
628 results:
1. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.
Takahashi S; Minnie SA; Ensbey KS; Schmidt CR; Sekiguchi T; Legg SRW; Zhang P; Koyama M; Olver SD; Collinge AD; Keshmiri S; Comstock ML; Varelias A; Green DJ; Hill GR
Blood; 2024 Apr; 143(16):1656-1669. PubMed ID: 38295333
[TBL] [Abstract] [Full Text] [Related]
2. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
Fadul CE; Thakur A; Kim J; Kassay-McAllister J; Schalk D; Lopes MB; Donahue J; Purow B; Dillon P; Le T; Schiff D; Liu Q; Lum LG
J Neurooncol; 2024 Jan; 166(2):321-330. PubMed ID: 38263486
[TBL] [Abstract] [Full Text] [Related]
3. bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8
Towers R; Trombello L; Fusenig M; Tunger A; Baumann AL; Savoldelli R; Wehner R; Fasslrinner F; Arndt C; Dazzi F; Von Bonin M; Feldmann A; Bachmann MP; Wobus M; Schmitz M; Bornhäuser M
Cancer Immunol Immunother; 2024 Jan; 73(1):8. PubMed ID: 38231344
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and validation of a novel lysosome-related gene signature for predicting prognosis and immune landscape in hepatocellular carcinoma.
Li H; Li J; Qu X; Dai H; Liu J; Ma M; Wang J; Dong W; Wang W
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17543-17557. PubMed ID: 37903936
[TBL] [Abstract] [Full Text] [Related]
5. Tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer.
Jacover A; Zarbiv Y; Tal KH; Klein S; Breuer S; Durst R; Avni B; Grisariu S; Stepensky P; Lotem M; Maimon O; Yablonski-Peretz T
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1894. PubMed ID: 37750497
[TBL] [Abstract] [Full Text] [Related]
6. A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.
Robinson T; Escara-Wilke J; Dai J; Zimmermann J; Keller ET
Prostate; 2023 Sep; 83(13):1247-1254. PubMed ID: 37244751
[TBL] [Abstract] [Full Text] [Related]
7. Modified Total en Bloc Spondylectomy with Self-Made Intervertebral Hook Blade in Spinal Tumors: A Retrospective Study.
Yang W; Zhang K; Lv J; Bai J; Li J; Tian Q; Wang Y; Lv Z; Feng Y
Orthop Surg; 2023 Jun; 15(6):1599-1606. PubMed ID: 37154111
[TBL] [Abstract] [Full Text] [Related]
8. (+)-Catechin Attenuates Multiple Atherosclerosis-Associated Processes In Vitro, Modulates Disease-Associated Risk Factors in C57BL/6J Mice and Reduces Atherogenesis in LDL Receptor Deficient Mice by Inhibiting Inflammation and Increasing Markers of Plaque Stability.
Chan YH; Moss JWE; Williams JO; Ferekidis N; Alshehri N; Hughes TR; Menendez-Gonzalez JB; Plummer SF; Michael DR; Rodrigues NP; Ramji DP
Mol Nutr Food Res; 2023 Jul; 67(14):e2200716. PubMed ID: 37150886
[TBL] [Abstract] [Full Text] [Related]
9. Deep learning on graphs for multi-omics classification of COPD.
Zhuang Y; Xing F; Ghosh D; Hobbs BD; Hersh CP; Banaei-Kashani F; Bowler RP; Kechris K
PLoS One; 2023; 18(4):e0284563. PubMed ID: 37083575
[TBL] [Abstract] [Full Text] [Related]
10. Integrative analyses of ferroptosis and immune related biomarkers and the osteosarcoma associated mechanisms.
Li G; Lei J; Xu D; Yu W; Bai J; Wu G
Sci Rep; 2023 Apr; 13(1):5770. PubMed ID: 37031292
[TBL] [Abstract] [Full Text] [Related]
11. Differentiating fulminant EBV infection complicated by HLH from Lymphoma: report of a case and a brief literature review.
Zehr B; Brannock K; Wyma R; Kahwash SB
Diagn Pathol; 2023 Feb; 18(1):28. PubMed ID: 36814281
[TBL] [Abstract] [Full Text] [Related]
12. Unique Reduced-Intensity Conditioning Haploidentical Peripheral Blood Stem Cell Transplantation Protocol for Patients with Hematologic Malignancy.
Xu J; Miao W; Yuan H; Liu Y; Chen G; Wang H; Aizezi G; Qu J; Duan X; Yang R; Muhashi M; Han C; Ding L; Abulaiti N; Pang N; Zhang L; Jiang M
Transplant Cell Ther; 2023 May; 29(5):331.e1-331.e8. PubMed ID: 36775200
[TBL] [Abstract] [Full Text] [Related]
13. Exploring the potential of combining il-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages.
Ehlers FAI; Mahaweni NM; van de Waterweg Berends A; Saya T; Bos GMJ; Wieten L
Cancer Immunol Immunother; 2023 Jun; 72(6):1789-1801. PubMed ID: 36656341
[TBL] [Abstract] [Full Text] [Related]
14. Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice.
Egli J; Heiler S; Weber F; Steiner G; Schwandt T; Bray-French K; Klein C; Fenn S; Lotz GP; Opolka-Hoffmann E; Kraft TE; Petersen L; Moser R; DeGeer J; Siegel M; Finke D; Bessa J; Iglesias A
MAbs; 2022; 14(1):2143009. PubMed ID: 36394299
[TBL] [Abstract] [Full Text] [Related]
15. Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate cancer.
Vaishampayan UN; Thakur A; Chen W; Deol A; Patel M; Dobson K; Dickow B; Schalk D; Schienschang A; Whitaker S; Polend A; Fontana JA; Heath EI; Lum LG
Clin Cancer Res; 2023 Jan; 29(1):122-133. PubMed ID: 36255393
[TBL] [Abstract] [Full Text] [Related]
16. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract] [Full Text] [Related]
17. FSH-blocking therapeutic for osteoporosis.
Gera S; Kuo TC; Gumerova AA; Korkmaz F; Sant D; DeMambro V; Sudha K; Padilla A; Prevot G; Munitz J; Teunissen A; van Leent MMT; Post TGJM; Fernandes JC; Netto J; Sultana F; Shelly E; Rojekar S; Kumar P; Cullen L; Chatterjee J; Pallapati A; Miyashita S; Kannangara H; Bhongade M; Sengupta P; Ievleva K; Muradova V; Batista R; Robinson C; Macdonald A; Hutchison S; Saxena M; Meseck M; Caminis J; Iqbal J; New MI; Ryu V; Kim SM; Cao JJ; Zaidi N; Fayad ZA; Lizneva D; Rosen CJ; Yuen T; Zaidi M
Elife; 2022 Sep; 11():. PubMed ID: 36125123
[TBL] [Abstract] [Full Text] [Related]
18. Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel.
Porter TJ; Lazarevic A; Ziggas JE; Fuchs E; Kim K; Byrnes H; Luznik L; Bolaños-Meade J; Ali SA; Shah NN; Wagner-Johnston N; Jain T
Br J Haematol; 2022 Dec; 199(5):720-727. PubMed ID: 36111395
[TBL] [Abstract] [Full Text] [Related]
19. The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
Xu N; Yu E; Ng N; Li M; Bujarski S; Hekmati A; Nassir I; Hekmati T; Yu J; Daniely D; Wang CS; Kim C; Chen H; Berenson JR
Hematol Oncol; 2023 Aug; 41(3):578-582. PubMed ID: 36043430
[TBL] [Abstract] [Full Text] [Related]
20. Road testing new CAR design strategies in multiple myeloma.
Rana PS; Murphy EV; Kort J; Driscoll JJ
Front Immunol; 2022; 13():957157. PubMed ID: 36016950
[TBL] [Abstract] [Full Text] [Related]
[Next]
